{"id":"NCT02727907","sponsor":"Biocad","briefTitle":"Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis","officialTitle":"International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-02-12","primaryCompletion":"2016-11-21","completion":"2017-08-11","firstPosted":"2016-04-05","resultsPosted":"2023-02-17","lastUpdate":"2023-02-17"},"enrollment":163,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"OTHER"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"BCD-033 (interferon beta 1a)","otherNames":[]},{"type":"DRUG","name":"Rebif (interferon beta 1a)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BCD-033","type":"EXPERIMENTAL"},{"label":"Rebif","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years. Study hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original drug RebifÂ®.","primaryOutcome":{"measure":"Number of Combined Unique Active Lesions","timeFrame":"52 weeks","effectByArm":[{"arm":"BCD-033","deltaMin":0,"sd":null},{"arm":"Rebif","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":["https://biocad.ru/we/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["flu-like syndrom","local reaction","neutropenia","fever","lymphopenia"]}}